<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781543</url>
  </required_header>
  <id_info>
    <org_study_id>HZNP-HZN-825-301</org_study_id>
    <secondary_id>2020-005764-62</secondary_id>
    <nct_id>NCT04781543</nct_id>
  </id_info>
  <brief_title>A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizon Therapeutics Ireland DAC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horizon Pharma Ireland, Ltd., Dublin Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial.&#xD;
      Participants will be screened within 4 weeks prior to the Baseline (Day 1) Visit.&#xD;
      Approximately 300 participants who meet the trial eligibility criteria will be randomized on&#xD;
      Day 1 in a 1:1:1 ratio to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52&#xD;
      weeks.&#xD;
&#xD;
      The trial will include up to a 4-week Screening Period and a 52-week Double-blind Treatment&#xD;
      Period. Participants will take their first dose of trial drug at the clinic and will return&#xD;
      to the clinic for trial visits at Week 4 and every 6 weeks thereafter until Week 52. All&#xD;
      participants who complete the Double-blind Treatment Period (Week 52) will be eligible to&#xD;
      enter a 52-week extension trial (HZNP-HZN-825-302, NCT not available yet). Participants not&#xD;
      entering the extension will return to the clinic for a Safety Follow-up Visit 4 weeks after&#xD;
      the last dose of trial drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FVC (forced vital capacity) percent predicted from Baseline to Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>As measured by a pulmonary function test called a spirometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HAQ-DI (Health Assessment Questionnaire - Disability Index) at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in MDGA (Physician Global Assessment) at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in PTGA (Patient Global Assessment) at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Physical Effects subscale of the scleroderma skin patient-reported outcome (SSPRO-18) at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Physical Limitations subscale of the scleroderma skin patient-reported outcome SSPRO-18 at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with an mRSS (modified Rodnan skin score) decrease of ≥5 points and 25% from Baseline at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate (defined as ACR-CRISS [predicted probability] of at least 0.6) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>American College of Rheumatology-Composite Response Index in Systemic Sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with an improvement in ≥3 of 5 core measures from Baseline: ≥20% in mRSS, ≥20% in HAQ-DI, ≥20% in PTGA, ≥20% in MDGA and ≥5% for FVC % predicted at Week 52 (ACR-CRISS-20)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>American College of Rheumatology-Composite Response Index in Systemic Sclerosis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diffuse Cutaneous Systemic Sclerosis</condition>
  <condition>Sclerosis, Systemic</condition>
  <arm_group>
    <arm_group_label>HZN-825 300 mg once daily (QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg oral tablets given in the morning and placebo in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HZN-825 300 mg twice daily (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg oral tablets given in the morning and evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be given orally in the morning and evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HZN-825 BID</intervention_name>
    <description>300 mg oral tablets BID</description>
    <arm_group_label>HZN-825 300 mg twice daily (BID)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HZN-825 QD</intervention_name>
    <description>300 mg oral tablets QD</description>
    <arm_group_label>HZN-825 300 mg once daily (QD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent.&#xD;
&#xD;
          2. Male or female between the ages of 18 and 75 years, inclusive, at Screening.&#xD;
&#xD;
          3. Meets the 2013 American College of Rheumatology/European League Against Rheumatism&#xD;
             classification criteria for SSc with a total score of ≥9 (Van den Hoogen et al.,&#xD;
             2013).&#xD;
&#xD;
          4. Classified as having skin involvement proximal to the elbow and knee (diffuse&#xD;
             cutaneous SSc subset by LeRoy and Medsger, 2001).&#xD;
&#xD;
          5. At the time of enrollment, less than 36 months since the onset of the first SSc&#xD;
             manifestation, other than Raynaud's phenomenon.&#xD;
&#xD;
          6. Skin thickening from SSc in the forearm suitable for repeat biopsy.&#xD;
&#xD;
          7. mRSS units ≥15 at Screening.&#xD;
&#xD;
          8. FVC ≥45% predicted at Screening, as determined by spirometry.&#xD;
&#xD;
          9. Willing and able to comply with the prescribed treatment protocol and evaluations for&#xD;
             the duration of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive for anti-centromere antibodies.&#xD;
&#xD;
          2. Diagnosed with sine scleroderma or limited cutaneous SSc.&#xD;
&#xD;
          3. Diagnosed with other autoimmune connective tissue diseases, except for fibromyalgia,&#xD;
             scleroderma-associated myopathy and secondary Sjogren's syndrome.&#xD;
&#xD;
          4. Scleroderma renal crisis diagnosed within 6 months of the Screening Visit.&#xD;
&#xD;
          5. Any of the following cardiovascular diseases:&#xD;
&#xD;
               1. uncontrolled, severe hypertension (≥160/100 mmHg) or persistent low blood&#xD;
                  pressure (systolic blood pressure &lt;90 mmHg) within 6 months of Screening,&#xD;
&#xD;
               2. myocardial infarction within 6 months of Screening,&#xD;
&#xD;
               3. unstable cardiac angina within 6 months of Screening.&#xD;
&#xD;
          6. DLCO &lt;40% predicted (corrected for hemoglobin). If severe acute respiratory syndrome&#xD;
             coronavirus 2 (SARS-CoV-2) exposure is of clinical concern for any subject, consider&#xD;
             using a DLCO up to 6 months before the Screening Visit.&#xD;
&#xD;
          7. Pulmonary arterial hypertension (PAH) by right heart catheterization requiring&#xD;
             treatment with more than 1 oral PAH-approved therapy or any parenteral therapy.&#xD;
             Treatment is allowed for erectile dysfunction and/or Raynaud's phenomenon/digital&#xD;
             ulcers.&#xD;
&#xD;
          8. Corticosteroid use for conditions other than SSc within 4 weeks prior to Screening&#xD;
             (topical steroids for dermatological conditions and inhaled/intranasal/intra-articular&#xD;
             steroids are allowed).&#xD;
&#xD;
          9. Use of any other non-steroid immunosuppressive agent, small biologic molecule,&#xD;
             cytotoxic or anti-fibrotic drug within 4 weeks of Screening, including&#xD;
             cyclophosphamide, azathioprine (Imuran®) or other immunosuppressive or cytotoxic&#xD;
             medication. Exceptions include mycophenolate mofetil (CellCept®), mycophenolic acid&#xD;
             (Myfortic®), methotrexate and low-dose prednisone, as follows: use of CellCept ≤3&#xD;
             g/day, Myfortic ≤2.14 g/day, methotrexate ≤15 mg/week and prednisone ≤10 mg/day (or&#xD;
             equivalent dosing of glucocorticoids) is allowed. See Table 9.1 for full details.&#xD;
             Subjects taking CellCept, Myfortic or methotrexate must have been doing so for ≥6&#xD;
             months and the dose must have been stable for ≥16 weeks prior to the Day 1 Visit.&#xD;
             Prednisone must have been at a stable dose for ≥8 weeks prior to the Day 1 Visit. It&#xD;
             is acceptable to be on background low-dose prednisone and anti-malarial drug along&#xD;
             with CellCept, Myfortic or methotrexate. Rituximab must not have been used within 6&#xD;
             months of the Day 1 Visit.&#xD;
&#xD;
         10. Known active bacterial, viral, fungal, mycobacterial or other infection, including&#xD;
             tuberculosis or atypical mycobacterial disease (fungal infections of nail beds are&#xD;
             allowed).&#xD;
&#xD;
         11. Use of a United States Food and Drug Administration-approved agent for SSc or an&#xD;
             investigational agent for any condition within 90 days or 5 half-lives, whichever is&#xD;
             longer, prior to Screening or anticipated use during the course of the trial.&#xD;
&#xD;
         12. Malignant condition in the past 5 years (except successfully treated basal/squamous&#xD;
             cell carcinoma of the skin or cervical cancer in situ).&#xD;
&#xD;
         13. Women of childbearing potential or male subjects not agreeing to use highly effective&#xD;
             method(s) of birth control throughout the trial and for 1 month after last dose of&#xD;
             trial drug. Male subjects must refrain from sperm donation and females from egg/ova&#xD;
             donation for this same time period.&#xD;
&#xD;
         14. Pregnant or lactating women.&#xD;
&#xD;
         15. Current drug or alcohol abuse or history of either within the previous 2 years, in the&#xD;
             opinion of the Investigator or as reported by the subject.&#xD;
&#xD;
         16. Previous enrollment in this trial or participation in a prior HZN-825 or SAR100842&#xD;
             clinical trial.&#xD;
&#xD;
         17. Known history of positive test for human immunodeficiency virus.&#xD;
&#xD;
         18. Active hepatitis (hepatitis B: positive hepatitis B surface antigen and positive&#xD;
             anti-hepatitis B core antibody [anti-HBcAb] and negative hepatitis B surface antibody&#xD;
             [HBsAb] or positive for HBcAb with a positive test for HBsAb and with presence of&#xD;
             hepatitis B virus DNA at Screening; hepatitis C: positive anti-hepatitis C virus&#xD;
             [anti-HCV] and positive RNA HCV).&#xD;
&#xD;
         19. Current alcoholic liver disease, primary biliary cirrhosis or primary sclerosing&#xD;
             cholangitis.&#xD;
&#xD;
         20. Previous organ transplant (including allogeneic and autologous marrow transplant).&#xD;
&#xD;
         21. International normalized ratio &gt;2, prolonged prothrombin time &gt;1.5 × the upper limit&#xD;
             of normal (ULN) or partial thromboplastin time &gt;1.5 × ULN at Screening.&#xD;
&#xD;
         22. Alanine aminotransferase or aspartate aminotransferase &gt;2 × ULN.&#xD;
&#xD;
         23. Estimated glomerular filtration rate &lt;30 mL/min/1.73 m^2 at Screening.&#xD;
&#xD;
         24. Total bilirubin &gt;2 × ULN. Subjects with documented diagnosis of Gilbert's syndrome may&#xD;
             be enrolled if their total bilirubin is ≤3.0 mg/dL.&#xD;
&#xD;
         25. Any other condition that, in the opinion of the Investigator, would preclude&#xD;
             enrollment in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farah Ali, MD</last_name>
    <role>Study Director</role>
    <affiliation>Horizon Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HorizonTherapeutics</last_name>
    <phone>866-479-6742</phone>
    <email>clinicaltrials@horizontherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Arthritis and Rheumatology Research, PLLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittney Blackwell</last_name>
      <phone>480-626-6657</phone>
      <email>brittney.blackwell@azarthritis.com</email>
    </contact>
    <investigator>
      <last_name>Saima Chohan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Arthritis Care Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Hasan</last_name>
      <phone>310-297-6812</phone>
      <email>elove1945@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Furst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRIS Research and Development LLC</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jhon Galindo</last_name>
      <phone>954-476-2338</phone>
      <email>jgalindo@irisrheumatology.com</email>
    </contact>
    <investigator>
      <last_name>Guillermo Valenzuela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DelRicht Clinical Research, LLC - ClinEdge - PPDS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Giorlando</last_name>
      <phone>504-336-2667</phone>
      <email>kgiorlando@delricht.com</email>
    </contact>
    <investigator>
      <last_name>Lesley Saketkoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tri Nguyen</last_name>
      <phone>214-879-6737</phone>
      <email>tnguyen@mcrcdallas.com</email>
    </contact>
    <investigator>
      <last_name>Stanley Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Physicians Rheumatology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Gonzales</last_name>
      <phone>713-500-7118</phone>
      <email>Patricia.Gonzales@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Maureen Mayes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scleroderma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

